Israeli pharmaceutical company Protalix Biotherapeutics Inc. has announced today that it has signed an agreement with Fundação Oswaldo Cruz (Fiocruz), an arm of Brazil’s health ministry, to supply its Gaucher treatment Uplyso.
The seven-year agreement is worth approx. $40 million a year, totaling at $280 million.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments